(European Society of Cardiology) A therapy that uses bone-marrow stem cells to promote heart repair did not significantly improve the primary outcome over a sham procedure among patients with congestive heart failure. However, it revealed critical new insights, according to investigators of the CHART-1 trial.
from EurekAlert! - Social and Behavioral Science http://ift.tt/2bZSkKA
No comments:
Post a Comment